Ratings by Piper Sandler (Christopher Raymond)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/20/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2025 | Q32 Bio Inc. | QTTB | Downgrade | Neutral (Overweight) |
3.15 (4.70) |
49.21% | Details | |
| 1/27/2025 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2025 | Blueprint Medicines | BPMC | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2025 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2025 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
25.16 (34.23) |
36.05% | Details | |
| 12/17/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2024 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2024 | Aclaris Therapeutis | ACRS | Upgrade | Overweight (Neutral) |
2.05 (1.45) |
-29.27% | Details | |
| 11/12/2024 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2024 | Tyra Biosciences | TYRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/11/2024 | Tyra Biosciences | TYRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/3/2024 | Tyra Biosciences | TYRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/3/2024 | Ardelyx, Inc | ARDX | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/25/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2024 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2024 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/30/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/27/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2024 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2024 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
21.49 (9.98) |
-53.56% | Details | |
| 8/2/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/2/2024 | Ardelyx, Inc | ARDX | Downgrade | Neutral (Overweight) |
7.57 (5.83) |
-22.99% | Details | |
| 7/2/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/1/2024 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/10/2024 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2024 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2024 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Blueprint Medicines | BPMC | Maintain | Neutral (N/A) |
|
Details | ||
| 4/29/2024 | Deciphera | DCPH | Downgrade | Neutral (Overweight) |
14.65 (25.59) |
74.68% | Details | |
| 4/15/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/9/2024 | Taysha Gene Therapies | TSHA | New Coverage | Overweight (N/A) |
2.68 (4.57) |
70.52% | Details | |
| 3/14/2024 | Solid Biosciences | SLDB | Upgrade | Overweight (Neutral) |
11.40 (6.75) |
-40.79% | Details | |
| 3/8/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2024 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Ardelyx, Inc | ARDX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2023 | Allovir Inc. | ALVR | Downgrade | Neutral (Overweight) |
2.33 (9.81) |
321.03% | Details | |
| 12/7/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2023 | Aclaris Therapeutis | ACRS | Downgrade | Neutral (Overweight) |
4.76 (2.05) |
-56.93% | Details | |
| 11/7/2023 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2023 | Deciphera | DCPH | Upgrade | Overweight (Neutral) |
10.15 (14.65) |
44.33% | Details | |
| 10/25/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2023 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/28/2023 | IO Biotech | IOBT | New Coverage | Overweight (N/A) |
1.28 (0.48) |
-62.5% | Details | |
| 9/25/2023 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2023 | Kinnate Biopharma | KNTE | Downgrade | Neutral (Overweight) |
1.70 (2.65) |
55.88% | Details | |
| 8/23/2023 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/1/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2023 | Akebia Therapeutics | AKBA | Upgrade | Overweight (Neutral) |
0.96 (1.27) |
32.29% | Details | |
| 5/23/2023 | VectivBio Holding AG | VECT | Downgrade | Neutral (Overweight) |
16.21 (16.85) |
3.95% | Details | |
| 5/4/2023 | Vertex | VRTX | New Coverage | Overweight (N/A) |
346.03 (456.69) |
31.98% | Details | |
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2023 | Kinnate Biopharma | KNTE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/17/2023 | Biogen | BIIB | Upgrade | Overweight (Neutral) |
289.70 (152.92) |
-47.21% | Details | |
| 2/9/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2023 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2022 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2022 | Ardelyx, Inc | ARDX | Upgrade | Overweight (Neutral) |
1.22 (6.19) |
407.38% | Details | |
| 11/17/2022 | Ardelyx, Inc | ardx | Upgrade | Overweight (Neutral) |
1.22 (7.57) |
520.49% | Details | |
| 11/14/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Solid Biosciences | SLDB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Regeneron Pharma | REGN | Maintain | (N/A) |
|
Details | ||
| 11/4/2022 | Amgen | AMGN | Maintain | (N/A) |
|
Details | ||
| 10/13/2022 | Otonomy | OTIC | Downgrade | Neutral (Overweight) |
0.26 (0.08) |
-69.23% | Details | |
| 9/28/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 9/13/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2022 | Aptinyx | APTX | Downgrade | Neutral (Overweight) |
0.60 (0.06) |
-90% | Details | |
| 8/9/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2022 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2022 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/1/2022 | VectivBio Holding AG | VECT | New Coverage | Overweight (N/A) |
5.70 (16.85) |
195.61% | Details | |
| 5/19/2022 | Solid Biosciences | SLDB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2022 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | Oncorus Inc. | ONCR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | Kinnate Biopharma | KNTE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | Graybug Vision | GRAY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2022 | Blueprint Medicines | BPMC | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2022 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2022 | Aptinyx | APTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2022 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2022 | Solid Biosciences | SLDB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2022 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2022 | Akebia Therapeutics | AKBA | Downgrade | Neutral (Overweight) |
2.44 (1.27) |
-47.95% | Details | |
| 3/3/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Otonomy | OTIC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/12/2022 | Biogen | BIIB | Downgrade | Neutral (Overweight) |
235.31 (184.87) |
-21.44% | Details | |
| 1/3/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2021 | Deciphera | DCPH | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2021 | Deciphera | DCPH | Downgrade | Neutral (Overweight) |
36.00 (25.59) |
-28.92% | Details | |
| 11/1/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2021 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/25/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
26.40 (75.01) |
184.13% | Details | |
| 7/29/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2021 | Ardelyx, Inc | ARDX | Downgrade | Neutral (Overweight) |
7.50 (6.19) |
-17.47% | Details | |
| 7/12/2021 | Solid Biosciences | SLDB | New Coverage | Neutral (N/A) |
3.45 (6.75) |
95.65% | Details | |
| 6/18/2021 | Biogen | BIIB | Upgrade | Overweight (Neutral) |
391.31 (184.87) |
-52.76% | Details | |
| 6/15/2021 | Aclaris Therapeutis | ACRS | New Coverage | Overweight (N/A) |
17.83 (4.76) |
-73.3% | Details | |
| 6/7/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2021 | Inovio Pharmaceuticals | INO | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2021 | Akebia Therapeutics | AKBA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2021 | Kinnate Biopharma | KNTE | New Coverage | Overweight (N/A) |
26.82 (2.65) |
-90.12% | Details | |
| 4/28/2021 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2021 | Oncorus Inc. | ONCR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/13/2021 | Otonomy | OTIC | New Coverage | Overweight (N/A) |
2.22 (0.26) |
-88.29% | Details | |
| 3/23/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2021 | Inovio Pharmaceuticals | INO | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2021 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2021 | Alexion Pharmaceuticals | ALXN | Downgrade | Neutral (Overweight) |
154.74 (182.01) |
17.62% | Details | |
| 2/4/2021 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2021 | Ardelyx, Inc | ARDX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/15/2020 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/27/2020 | Aptinyx | APTX | New Coverage | Overweight (N/A) |
3.13 (0.06) |
-98.08% | Details | |
| 10/27/2020 | Oncorus Inc. | ONCR | New Coverage | Overweight (N/A) |
15.51 (0.12) |
-99.23% | Details | |
| 10/20/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/6/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/31/2020 | Aimmune Therapeutics | AIMT | Downgrade | Neutral (Overweight) |
12.60 (34.49) |
173.73% | Details | |
| 8/18/2020 | iTeos Therapeutics | ITOS | New Coverage | Overweight (N/A) |
31.40 (10.15) |
-67.68% | Details | |
| 7/29/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/19/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/9/2020 | Prevail Therapeutics | PRVL | New Coverage | Overweight (N/A) |
12.36 (23.00) |
86.08% | Details | |
| 3/13/2020 | Inovio Pharmaceuticals | INO | Downgrade | Neutral (Overweight) |
8.37 (1.74) |
-79.21% | Details | |
| 2/25/2020 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2020 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2020 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2020 | AMAG Pharmaceuticals | AMAg | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2020 | Inovio Pharmaceuticals | INO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/3/2019 | Audentes Therapeutics | BOLD | Downgrade | Neutral (Overweight) |
29.03 (1.13) |
-96.11% | Details | |
| 11/12/2019 | Akebia Therapeutics | AKBA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2019 | Rockwell Medical Technologies | RMTI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2019 | AMAG Pharmaceuticals | AMAG | Downgrade | Underweight (Neutral) |
13.33 (9.40) |
-29.48% | Details | |
| 10/17/2019 | Ardelyx, Inc | ARDX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2019 | Aimmune Therapeutics | AIMT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/1/2019 | Aimmune Therapeutics | AIMT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2019 | Aimmune Therapeutics | AIMT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2019 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2019 | Blueprint Medicines | BPMC | New Coverage | Neutral (N/A) |
77.72 (129.46) |
66.57% | Details | |
| 8/26/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2019 | Abbvie | ABBV | Upgrade | Overweight (Neutral) |
66.56 (198.05) |
197.55% | Details | |
| 7/24/2019 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/18/2019 | Akebia Therapeutics | AKBA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2019 | Biogen | BIIB | Downgrade | Neutral (Overweight) |
238.07 (184.87) |
-22.35% | Details | |
| 6/26/2019 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/24/2019 | Rockwell Medical Technologies | RMTI | New Coverage | Overweight (N/A) |
3.02 (0.87) |
-71.19% | Details | |
| 6/3/2019 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2019 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2019 | Audentes Therapeutics | BOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2019 | Ardelyx, Inc | ARDX | New Coverage | Overweight (N/A) |
3.07 (6.19) |
101.63% | Details | |
| 3/21/2019 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2019 | Sophiris Bio | SPHS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2019 | Audentes Therapeutics | BOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2018 | Audentes Therapeutics | BOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2018 | AMAG Pharmaceuticals | AMAG | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2018 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2018 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/2/2018 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2018 | Inovio Pharmaceuticals | INO | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/17/2018 | Tesaro | TSRO | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/4/2018 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2018 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2018 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details |
